{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2(3)"],"submitter":["Bagno FF"],"pubmed_abstract":["There is a massive demand to identify alternative methods to detect new cases of COVID-19 as well as to investigate the epidemiology of the disease. In many countries, importation of commercial kits poses a significant impact on their testing capacity and increases the costs for the public health system. We have developed an ELISA to detect IgG antibodies against SARS-CoV-2 using a recombinant viral nucleocapsid (rN) protein expressed in <i>E. coli</i>. Using a total of 894 clinical samples we showed that the rN-ELISA was able to detect IgG antibodies against SARS-CoV-2 with high sensitivity (97.5%) and specificity (96.3%) when compared to a commercial antibody test. After three external validation studies, we showed that the test accuracy was higher than 90%. The rN-ELISA IgG kit constitutes a convenient and specific method for the large-scale determination of SARS-CoV-2 antibodies in human sera with high reliability."],"journal":["Journal of clinical virology plus"],"pagination":["100101"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9356643"],"repository":["biostudies-literature"],"pubmed_title":["Development and validation of an enzyme-linked immunoassay kit for diagnosis and surveillance of COVID-19."],"pmcid":["PMC9356643"],"pubmed_authors":["Sergio SAR","Fernandes APSM","Aguiar A","Gazzinelli RT","Durigon EL","Teixeira SMR","Soares CP","Ferreira AGP","da Fonseca FG","Almeida FJ","Bagno FF","Figueiredo MM","Godoi LC","Andrade LAF","Salazar NC","da Silva ED"],"additional_accession":[]},"is_claimable":false,"name":"Development and validation of an enzyme-linked immunoassay kit for diagnosis and surveillance of COVID-19.","description":"There is a massive demand to identify alternative methods to detect new cases of COVID-19 as well as to investigate the epidemiology of the disease. In many countries, importation of commercial kits poses a significant impact on their testing capacity and increases the costs for the public health system. We have developed an ELISA to detect IgG antibodies against SARS-CoV-2 using a recombinant viral nucleocapsid (rN) protein expressed in <i>E. coli</i>. Using a total of 894 clinical samples we showed that the rN-ELISA was able to detect IgG antibodies against SARS-CoV-2 with high sensitivity (97.5%) and specificity (96.3%) when compared to a commercial antibody test. After three external validation studies, we showed that the test accuracy was higher than 90%. The rN-ELISA IgG kit constitutes a convenient and specific method for the large-scale determination of SARS-CoV-2 antibodies in human sera with high reliability.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2024-10-16T03:41:43.488Z","creation":"2024-10-16T03:41:43.488Z"},"accession":"S-EPMC9356643","cross_references":{"pubmed":["35959109"],"doi":["10.1016/j.jcvp.2022.100101"]}}